AC Immune reports positive ACI-7104 data and CHF 73.9 million cash in Q3 2026
AI Summary- AC Immune advanced ACI-7104 and other wholly owned neurodegenerative disease programs.
- CHF 73.9 million in cash resources remained at September 30, 2026.
- Further ACI-7104 data are expected before year-end, with ACI-19764 results in early 2027.